Interaction between aspirin and angiotensin-converting enzyme inhibitors: Should they be used together in older adults with heart failure?

Journal of the American Geriatrics Society

Volumn 50, Issue 7, 2002, Pages 1293-1296

  Ahmed, Ali ^a,b,c  

^a Nutrition Sciences and Medicine   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; BRADYKININ; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PHOSPHOLIPASE A2; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; THROMBOXANE;

ACUTE HEART INFARCTION; AGED; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; MORTALITY; NOTE; VASODILATATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CLINICAL TRIALS; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS;

EID: 0036063181     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1532-5415.2002.50320.x     Document Type: Note

References (34)

1. Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function
2. Secondary prevention of vascular disease by prolonged antiplatelet treatment
3. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
4. Final report on the aspirin component of the ongoing Physicians' Health Study
5. Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials
6. An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease
7. The coxibs, selective inhibitors of cyclooxygenase-2
8. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients
9. Effect of low-dose aspirin on thromboxane production and the antihypertensive effect of captopril
10. Lack of impact of low-dose acetyl-salicylic acid on kidney function in type 1 diabetic patients with microalbuminuria
11. Angiotensin II receptor antagonists
12. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure
13. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
14. Effects of captopril on peripheral hemodynamics in severe congestive heart failure
15. The angiotensin-converting enzyme inhibitor and aspirin interaction in congestive heart failure: Fear or reality?
16. Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function
17. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: Results of a double-blind, randomized comparative trial
18. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure
19. Antiplatelet agents and survival: A cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial
20. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: Subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)
21. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
22. ACE inhibition in cardiovascular disease
23. The HOPE Trial - A discussion with Salim Yusuf, Peter Sleight, Bertram Pitt, Eva Lonn, and Victor Dzau (based on the transcript of a discussion that took place after a session at the American College of Cardiology Scientific Session 2000, March 12-15, 2000, Anaheim, California.)
24. Aspirin and the treatment of heart failure in the elderly
25. Effect of combined aspirin and angiotensin-converting enzyme inhibitor therapy versus angiotensin-converting enzyme inhibitor therapy alone on readmission rates in heart failure
26. Aspirin and angiotensin-converting enzyme inhibitors among elderly survivors of hospitalization for an acute myocardial infarction
27. Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease
28. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: Systematic overview of individual data from 96,712 randomized patients
29. WASH (The Warfarin/Aspirin Study of Heart Failure: A study comparing the effects of aspirin, warfarin and no anti-thrombotic therapy on long-term clinical outcomes among patients with heart failure
30. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics
31. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: An underrecognized public health problem
32. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin 11 receptor blocker therapy in heart failure
33. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives
34. Comparison of candesartan, enal-april, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study